Share on facebook
Share on twitter
Share on linkedin

June 9, 2016: BioAegis Therapeutics and TH Chan Harvard School of Public Health Awarded 3-Year $2.8MM NIH Grant to Study Plasma Gelsolin Immunotherapy to Limit Antibiotic-Resistant Pneumonia

National Institute of Allergy and Infectious Diseases awarded a 3-year $ 2.8 million grant to a partnership between BioAegis and TH Chan Harvard School of Public Health researchers. The grant will advance the study of pGSN replacement as a therapy for antibiotic-resistant pneumonia. The highly competitive R01 grant was responsive to a Request for Applications entitled: “Partnerships for the Development of Host-Targeted Therapeutics to Limit Antimicrobial Resistance.”

Read the full release NIH Grant Press Release June 9 2016